Top

Cancer Chemotherapy and Pharmacology

Published in:

01-01-2011 | Original Article

Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets

Authors: Dae Ho Lee, Sang-We Kim, Cheolwon Suh, Yun Hee Han, Jung-Shin Lee

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2011

Abstract

Purpose

This phase II study evaluated efficacy of single-agent erlotinib for chemotherapy-naïve patients with advanced/metastatic NSCLC who were ineligible for platinum doublets.

Methods

Chemotherapy-naive patients but ineligible for platinum doublets (aged 18–75 with an ECOG performance status [PS] 2–3; or aged 76 or older with an ECOG PS 1–3) were enrolled and treated with erlotinib 100 mg once daily till disease progression, unacceptable toxicity or patient’s refusal.

Results

Out of 24 patients enrolled, 5 reached a PR, giving an overall response rate of 21%, but all responders were never-smokers with adenocarcinoma. According to EGFR mutation status, PR was observed in two of three patients having mutant EGFR (67%) but in one of nine having wild-type EGFR (11%). With a median follow-up of 22.6 months, the median progression-free and overall survival was 1.5 months and 3.2 months, respectively. All responders to post-erlotinib chemotherapy had responded to prior erlotinib.

Conclusions

For unselected chemotherapy-naïve Asian patients with NSCLC but ineligible for platinum doublets, empirical use of upfront erlotinib could not be recommended because of poor survival outcome. However, this can be given to selected subsets based on molecular or clinical predictors.

Pfister DG, Johnson DH, Azzoli CG et al (2004) American society of clinical oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J Clin Oncol 22:330–353CrossRefPubMed

Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 355:2542–2550CrossRefPubMed

Ebi N, Semba H, Tokunaga SJ et al (2008) A phase II trial of gefitinib monotherapy in chemotherapy-naive patients of 75 years or older with advanced non-small cell lung cancer. J Thorac Oncol 3:1166–1171CrossRefPubMed

Crino L, Cappuzzo F, Zatloukal P et al (2008) Gefitinib versus vinorelbine in chemotherapy-naïve elderly patients with advanced non-small cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 26:4253–4260CrossRefPubMed

Goss G, Ferry D, Wierzbicki R et al (2009) Randomized phase II study of gefitinib compared with placebo in chemotherapy-naïve patients with advanced non-small cell lung cancer and poor performance status. J Clin Oncol 27:2253–2260CrossRefPubMed

Shepherd FA, Rodrigues Pereira JR, Ciuleanu T et al (2005) Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353:123–132CrossRefPubMed

Thatcher N, Chang A, Parikh P et al (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized placebo-controlled, multicenter study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527–1537CrossRefPubMed

Cho BC, Im CK, Park MS et al (2007) Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. J Clin Oncol 25:2528–2533CrossRefPubMed

Lee DH, Kim SW, Suh C et al (2008) Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. Ann Oncol 19:2039–2042CrossRefPubMed

10.

Lilenbaum R, Axelrod R, Thomas S et al (2008) Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 26:863–869CrossRefPubMed

11.

Hesketh PJ, Chansky K, Wozniak AJ et al (2008) Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2. J Thorac Oncol 3:1026–1031CrossRefPubMed

12.

Inoue A, Kobayashi K, Usui K et al (2009) First-line gefitinib for patients with advanced non–small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 27:1394–1400CrossRefPubMed

13.

Pas-Ares L, Sanchez JM, Garcia-Velasco A et al. (2006) Prospective phase II trial of erlotinib in advanced non–small-cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol 24 (Suppl): 369s, abstr 7020

14.

Mok T, Wu Yi-L, Thongprasert S et al. (2008) Phase III randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced NSCLC (I-PASS). Ann Oncol 19 (Suppl 8): viii1, abstr LBA2

15.

Mitsudomi T, Kosaka T, Endoh H et al (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23:2513–2520CrossRefPubMed

16.

Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306–13311CrossRefPubMed

17.

Inoue A, Suzuki T, Fukuhara T et al (2006) Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24:3340–3346CrossRefPubMed

18.

Lee DH, Han JY, Lee HG et al (2005) Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 11:3032–3037CrossRefPubMed

19.

Cappuzzo F, Gigorio C, Janne PA et al (2007) Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol 25:2248–2255CrossRefPubMed

Title: Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets
Authors: Dae Ho Lee
Sang-We Kim
Cheolwon Suh
Yun Hee Han
Jung-Shin Lee
Publication date: 01-01-2011
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2011
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-010-1280-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2011

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin

Effects of methimazole on the elimination of irinotecan

Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase

Clinical characteristics and treatment outcomes of gastric cancer patients with isolated para-aortic lymph node involvement

Ultrasound-guided intratumoral administration of collagenase-2 improved liposome drug accumulation in solid tumor xenografts

Keynote webinar | Spotlight on antibody–drug conjugates in cancer